Clinical trials: Neoplasm Metastasis
Breast Cancer
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia
Planned study population consists of approximately 1,000 adult patients with HER2-positive mBC receiving anti-HER2 therapy in about 50 oncological centers (in each center it is expected to recruit about 20 patients) in different…
- Trial name
- NCT05905939
- Where
- 29 sites in Russia
- Volunteers
- 774 people
- Sponsor
- AstraZeneca
Advanced/Metastatic Solid Tumors
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and…
- Trial name
- NCT06922357
- Testing
- HRS-6719
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-naïve participants with locally advanced or metastatic squamous non-small cell lung cancer.
- Trial name
- NCT02941601
- Testing
- Necitumumab, Gemcitabine, Carboplatin
- Where
- 19 sites in United States, Belgium and 5 more
- Sponsor
- Eli Lilly and Company
Neoplasms, Gastrointestinal Tract
Study of GSK1363089 in Metastatic Gastric Cancer
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
- Trial name
- NCT00725712
- Testing
- GSK1363089 (formerly XL880)
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Endometrial Cancer
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic…
- Trial name
- NCT07054567
- Testing
- BL-B01D1, Pembrolizumab, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Prostatic Neoplasms
MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.
- Trial name
- NCT00302471
- Testing
- Comparator: MK0429
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Effectiveness of KOS-862 in the Treatment of Lung Cancer
The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior…
- Trial name
- NCT00080509
- Testing
- KOS-862
- Volunteers
- 85 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma, BRAF V600 Mutation Positive
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing…
- Trial name
- NCT02608034
- Testing
- Itraconazole, Rifampin, Vemurafenib
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 32 people
- Sponsor
- Genentech, Inc.
Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal…
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Trial name
- NCT03412799
- Testing
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Where
- 7 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Panbela Therapeutics, Inc.
Carcinoma, Ductal, Breast, Breast Cancer
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
- Trial name
- NCT02983071
- Testing
- G1T38, Fulvestrant
- Where
- 8 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 102 people
- Sponsor
- G1 Therapeutics, Inc.
Liposarcoma, Leiomyosarcoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
- Trial name
- NCT00060944
- Testing
- Yondelis, Dexamethasone
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Colon Cancer, Colorectal Cancer
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer
- Trial name
- NCT00094809
- Testing
- Pegfilgrastim
- Volunteers
- 252 people
- Sponsor
- Amgen
Solid Tumor, Adult
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
- Trial name
- NCT06554795
- Testing
- DB-1419
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- DualityBio Inc.
Solid Tumor
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
- Trial name
- CXCessoR4 (NCT02472977)
- Testing
- Ulocuplumab, Nivolumab
- Where
- 7 sites in United States, Finland
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone…
- Trial name
- NCT01288911
- Testing
- enzalutamide, bicalutamide
- Where
- 88 sites in United States, Belgium and 6 more
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Advanced or Metastatic Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors.
- Trial name
- NCT05017012
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab, Pemetrexed
- Where
- 22 sites in Chile, Hungary and 4 more
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow…
- Trial name
- NCT07757230
- Testing
- SSGJ-612 (HER2-targeted antibody), HER2-targeted ADC
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Thyroid Cancer
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local…
- Trial name
- NCT00121628
- Testing
- AMG 706
- Volunteers
- 184 people
- Sponsor
- Amgen